BMY Overview
Upcoming Projects (BMY)
-
Evaluating Phase 3 POETYK PsA-1 Trial Results for Deucravacitinib (Sotyktu) in Psoriatic Arthritis from Bristol Myers Squibb
Ticker: BMY
Execute By: Dec 31, 2025
Executed Projects (BMY)
-
Discussing current use of Cobenfy (KarXT) in treating patients with schizophrenia
Tickers: BMY, ABBV
Executed On: Apr 25, 2025 at 09:00 AM EDT -
Discussing Rytelo (Imetelstat) use in LR-MDS and expectations for trends over the coming year
Tickers: GERN, BMY
Executed On: Mar 27, 2025 at 11:00 AM EDT -
Discussing the launch of Cobenfy (KarXT), an oral antipsychotic which was recently approved by the FDA for the treatment of schizophrenia.
Ticker: BMY
Executed On: Jan 24, 2025 at 02:30 PM EST -
Discussing the recent FDA approval of Cobenfy (KarXT), an oral antipsychotic developed by BMS and Karuna for the treatment of schizophrenia.
Ticker: BMY
Executed On: Nov 13, 2024 at 06:30 PM EST -
Discussing BTK inhibitors in autoimmune indications
Tickers: NVS, BMY, GILD, SNY
Executed On: Oct 01, 2024 at 01:30 PM EDT -
Discussing the treatment landscape for ROS1 NSCLC and the potential of taletrectinib
Tickers: NUVB, NUVL, BMY, PFE
Executed On: Sep 24, 2024 at 11:00 AM EDT -
Advancing Melanoma Treatment: Insights into Iovance Biotherapeutics, Inc.'s Lifileucel and Pembrolizumab Combination, following ASCO
Tickers: IOVA, BMY
Executed On: Jun 14, 2024 at 07:20 AM EDT -
Discussing the Adagrasib/Cetuximab Combination Therapy in KRAS G12C–Mutant Colorectal Cancer ahead of the PDUFA
Ticker: BMY
Executed On: Jun 05, 2024 at 11:00 AM EDT -
Navigating New Frontiers in Follicular Lymphoma: An In-depth Look at Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel)
Ticker: BMY
Executed On: May 16, 2024 at 11:00 AM EDT -
Discussing the New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia
Ticker: BMY
Executed On: Apr 23, 2024 at 10:00 AM EDT -
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - October 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Nov 02, 2023 at 05:25 PM EDT -
Discussing Novel Therapies in Dermatology with a focus on TYK2 in Psoriasis, IL-13 & OX-40(L) in Atopic Dermatitis and IL-17 in Hidradenitis Suppurativa
Tickers: REGN, BMY, AMGN
Executed On: Oct 18, 2023 at 12:30 PM EDT -
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - July 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Aug 01, 2023 at 03:55 PM EDT -
Discussing various agents targeting BCMA and GPRC5D in multiple myeloma
Tickers: JNJ, LEGN, BMY
Executed On: Jul 12, 2023 at 06:00 PM EDT -
A Second Opinion: Discussing Bristol Myers' COMMANDS (Reblozyl) & Geron's iMERGE (imetelstat) data from ASCO 2023 in MDS
Tickers: BMY, GERN
Executed On: Jun 26, 2023 at 01:00 PM EDT -
Discussing Bristol Myers' COMMANDS (Reblozyl) & Geron's iMERGE (imetelstat) data from ASCO 2023 in MDS
Tickers: BMY, GERN
Executed On: Jun 07, 2023 at 02:00 PM EDT -
Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma
Ticker: BMY
Executed On: May 18, 2023 at 09:30 AM EDT -
Quarterly Survey: BMY's Reblozyl (luspatercept) and LR-MDS requiring Red Blood Cell Transfusions May 2023
Tickers: BMY, XLRN, MRK, GERN
Executed On: May 10, 2023 at 12:29 PM EDT -
Digging into the Phase 1 data for REGN's LAG3 + Libtayo combination in frontline Melanoma
Tickers: REGN, BMY
Executed On: Oct 21, 2022 at 02:00 PM EDT -
Digging into S1P1 modulators as treatment for Ulcerative Colitis with a focus on Zeposia (Ozanimod), Etrasimod, CBP-307 & VTX002
Tickers: BMY, PFE, CNTB, VTYX
Executed On: Sep 23, 2022 at 02:00 PM EDT -
A look at the use of ELIQUIS, Xarelto, and other blood thinners for cardiovascular disease and atrial fibrillation
Tickers: BMY, JNJ
Executed On: Aug 25, 2022 at 02:00 PM EDT -
A Second Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Tickers: BMY, LIAN
Executed On: Jun 30, 2022 at 09:00 AM EDT -
A Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Tickers: BMY, LIAN
Executed On: Jun 29, 2022 at 02:00 PM EDT -
A look into the current and developing S1P1 modulators as treatment for Ulcerative Colitis
Tickers: PFE, BMY, CNTB, VTYX
Executed On: Apr 22, 2022 at 01:00 PM EDT -
A look at the potential of S1P modulators in moderate-severe ulcerative colitis and how they might fit into the treatment paradigm
Tickers: ARNA, BMY, CNTB
Executed On: Mar 07, 2022 at 12:00 PM EST
Expired Projects (BMY)
-
Discussing the clinical landscape of multiple myeloma with a focus on BCMA CAR-T
Tickers: LEGN, JNJ, TSVT, BMY
Execute By: Oct 31, 2023 -
Discussing various modalities for BCMA targeted therapy in multiple myeloma
Tickers: JNJ, LEGN, BMY
Execute By: Oct 27, 2023 -
Discussing recent advancements in dermatology, with a focus on AD and psoriasis
Tickers: LEGN, BMY, JNJ
Execute By: Oct 27, 2023 -
Discussing TGTX's Umbralisib UNITY-NHL Trial In wake of Rolling NDA Submission in Marginal Zone Lymphoma/Follicular Lymphoma
Tickers: TGTX, BMY, BAYN.XFRA
Execute By: Apr 03, 2020
Upcoming & Overdue Catalysts (BMY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BMY)
-
Nektar (NKTR), Bristol-Myers (BMY) to end development program for bempegaldesleukin/Opdivo
Tickers: BMY, NKTR
Occurred on: Apr 14, 2022 -
Celgene's (CELG) INREBIC (Fedratinib) gains FDA Approval as once-daily oral treatment in Myelofibrosis (bone marrow cancer)
Tickers: CELG, BMY
Occurred on: Aug 16, 2019 -
PRM-151 (pentraxin-2) Advances into Phase 2 Stage for Myelofibrosis - Study to Complete in 2017
Ticker: BMY
Occurred on: Jun 25, 2018 -
Phase 1/2 preliminary results of NKTR-214 (PEG-rhuIL-2) in combination with nivolumab in advanced solud tumors (PIVOT trial)
Tickers: NKTR, BMY
Occurred on: Jun 02, 2018 -
Phase 3 Data of Prostvac for Prostate Cancer Due Second Half of 2017
Tickers: 0DPB.L, BMY
Occurred on: Sep 14, 2017 -
Data available 2H from Phase III study of Empliciti in first-line multiple myeloma
Tickers: BMY, ABBV
Occurred on: Jun 24, 2017 -
FDA Approves Metformin Intellipharmaceutics' (IPCI) Generic Form of Bristol-Myers Squibb's (BMY) Type 2 Diabetes Med Glucophage XR
Tickers: IPCI, BMY
Occurred on: Feb 25, 2017 -
Bristol-Myers Squibb (BMY) Announces $2 Billion Accelerated Share Repurchase Program
Ticker: BMY
Occurred on: Feb 21, 2017 -
Bristol-Myers Squibb (BMY) Fails Phase 2 EkkiKIR Trial Evaluating Innate Pharma's (IPHYF) Lirilumab in Treatment of Acute Myeloid Leukemia (AML)
Tickers: BMY, IPHYF
Occurred on: Feb 06, 2017 -
Japanese Authorities Mandate 50% Price Decrease for Bristol-Myers Squibb's (BMY) Cancer Medication Opdivo
Ticker: BMY
Occurred on: Nov 17, 2016 -
Bristol-Myers Squibb Announces Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 = 5%
Ticker: BMY
Occurred on: Aug 05, 2016 -
Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment Options for Advanced Non-Small-Cell Lung Cancer”
Ticker: BMY
Occurred on: Jun 29, 2016 -
EMA Decision on Regulatory Filings for Empliciti for Approval in Europe Due by April 1
Tickers: BMY, ABBV
Occurred on: May 11, 2016 -
Development of Varlilumab and Nivolumab (Opdivo) to Advance to Phase 2 Study - Open Enrollment to Begin Q2 of 2016
Tickers: CLDX, BMY
Occurred on: Apr 18, 2016 -
Bristol-Myers Squibb Completes Previously Announced Sale of its HIV R&D Portfolio to ViiV Healthcare
Ticker: BMY
Occurred on: Feb 22, 2016 -
Bristol-Myers Squibb (BMY) Acquires Cardioxyl Pharma for $2.1 Billion
Tickers: BMY, Cardioxyl Pharma
Occurred on: Nov 02, 2015 -
Bristol-Myers Squibb (BMY) Announces Complete Phase 2a Proof-of-Concept Study of BMS-955176 in Treatment of HIV-1
Tickers: BMY, GILD
Occurred on: Oct 23, 2015 -
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015
Strategic Initiatives (BMY)
-
Prothena (PRTA) Announces Bristol Myers Squibb (BMY) Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Tickers: PRTA, BMY
Announcement Date: Jun 24, 2021 -
Schrödinger (SDGR) Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb (BMY)
Tickers: SDGR, BMY
Announcement Date: Nov 23, 2020 -
Bristol-Myers Squibb (BMY) Enters Collaboration Agreement with Calithera Biosciences (CALA) to Evaluating Opdivo + CB-839 in Clear Cell Renal Cell Carcinoma
Tickers: CALA, BMY
Announcement Date: Dec 21, 2016 -
Rosetta Genomics (ROSG) Enters Research Collaboration to Develop Test Predicting Response to Bristol-Myers Squibb's (BMY) Opdivo
Tickers: ROSG, BMY
Announcement Date: Nov 21, 2016 -
Roche (RHHBY) and Bristol-Myers Squibb (BMY) Announce Decrease in Cancer Drug Prices for Access to Britain's National Health Service (NHS)
Tickers: BMY, RHHBY
Announcement Date: Nov 17, 2016 -
Bristol-Myers Squibb (BMY) Announces Collaboration Agreement with Enterome to Develop Microbiome-Derived Biomarkers for Cancer
Tickers: BMY, Enterome
Announcement Date: Nov 16, 2016 -
Bristol-Myers Squibb (BMY) and Infinity Pharma (INFI) Announce Collaboration Agreement to Study Opdivo and IPI-549 in Patients with Advanced Solid Tumors
Tickers: INFI, BMY
Announcement Date: Nov 09, 2016 -
Lexicon Pharma (LXRX) Acquires Exclusive Research Rights from Bristol-Myers Squibb (BMY) for Neuropathic Pain Candidate LX9211
Tickers: BMY, LXRX
Announcement Date: Nov 07, 2016 -
Bristol-Myers Squibb (BMY) Announces Evolution Plan to Increase Investment in Research and Development
Ticker: BMY
Announcement Date: Oct 27, 2016 -
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Tickers: JNJ, BMY
Announcement Date: Jul 26, 2016 -
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Tickers: BMY, ABBV
Announcement Date: Jul 25, 2016 -
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Tickers: BMY, Cormorant Pharmaceuticals
Announcement Date: Jul 05, 2016 -
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
Tickers: BMY, PsiOxus Therapeutics
Announcement Date: Jun 30, 2016 -
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Tickers: BMY, PFE, PTLA
Announcement Date: Feb 02, 2016 -
Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration
Tickers: ALONC.PA, BMY
Announcement Date: Jan 05, 2016
